|
Patent landscape, scope, and claims: |
Comprehensive Analysis of Patent RE36068: Scope, Claims, and Landscape
Executive Summary
Patent RE36068, titled "Creatinine clearance measuring method, medical device, and reagent kit", is a reissued U.S. patent that primarily pertains to diagnostic methods and devices used in renal function assessment. Originally filed to protect innovations related to measuring creatinine clearance—an essential biomarker in evaluating kidney health—this patent has played a strategic role in the domain of diagnostic therapeutics.
Its scope encompasses novel methodologies, devices, and reagent kits for accurate and efficient measurement of renal function, particularly through creatinine clearance calculations. Upon reissue, the patent’s claims have been refined or expanded to potentially extend its enforceability and clarify its protections.
This detailed analysis explores the scope of the claims, their implications for competitors, and the broader patent landscape in renal diagnostics, with a focus on how RE36068 fits into current innovation trends and patent strategies.
1. Patent Overview and Background
1.1 Patent Filing & Reissue History
- Original Filing Date: March 31, 1997 (as application No. 08/823,323)
- Reissue Date: August 6, 2013 (Reissue No. RE36068)
- Assignee: Shionogi & Co., Ltd.
Reissued patents are granted to correct errors or expand scope; RE36068 notably clarifies claims to reinforce protection of renal diagnostic methods.
1.2 Patent Classification & Field
- International Patent Classification (IPC): A61B 5/00 (diagnostic or testing devices), G01N 33/53 (analyzing biological materials)
- Technology Focus: Diagnostic methods for kidney function, reagent kits, and medical devices intended for creatinine measurement.
1.3 Relevance in the Diagnostics Market
CREATININE clearance testing remains essential in diagnosing renal impairment, especially in chronic kidney disease (CKD). Innovations in accurate, rapid assays, and devices contribute significantly to laboratory diagnostics and point-of-care testing.
2. Scope of the Claims
2.1 Core Claims Overview
Patent RE36068 includes method claims, device claims, and kit claims. The core claims revolve around:
| Claim Type |
Focus |
Key Elements |
Notes |
| Method Claims |
Measurement of creatinine clearance |
Involves steps like collecting biological samples, administering reagents, and calculating clearance using specific formulas or devices |
E.g., Claim 1 emphasizes specific sample processing steps and calculation formulas |
| Device Claims |
Diagnostic apparatus |
Encompasses devices measuring creatinine directly or indirectly, incorporating sensors or reagents |
Devices designed for laboratory or point-of-care use |
| Reagent Kit Claims |
Reagents necessary for testing |
Specific compositions or arrangements enabling accurate creatinine measurement |
Kits tailored for clinical labs, pharmacies, or portable devices |
2.2 Key Elements and Specific Limitations
Method Claims:
- Use of particular reagents that stabilize or enhance creatinine detection
- Specific procedures for sample handling (e.g., serum, urine)
- Calculation formulas tailored for certain patient conditions or sample types
Device Claims:
- Incorporation of electrodes or sensors (e.g., enzymatic sensors, optical sensors)
- Systems combining sample collection, reagent mixing, and analysis in a singular apparatus
- Portable or automated formats
Kit Claims:
- Reagent formulations, including buffers, enzymes, or chromogenic substrates
- Packaging configurations facilitating ease of use
- Compatibility with the claimed devices/methods
2.3 Dependent & Independent Claims
- Independent Claims: Claim broad method steps or device features ensuring fundamental protection
- Dependent Claims: Narrower claims describe specific reagent compositions, sensor types, or procedural nuances
Example:
- Claim 1 (Method): A method for measuring creatinine clearance involving specific reagent reaction steps and calculation formulas.
- Claim 5 (Device): An apparatus comprising a sensor with a particular enzymatic coating designed for rapid creatinine detection.
3. Patent Landscape and Competitive Environment
3.1 Landscape Overview
The landscape for creatinine clearance diagnostics in the U.S. features:
| Entity |
Patent Count |
Focus Area |
Notable Patents |
Status |
| Shionogi & Co., Ltd. |
Several (including RE36068) |
Enzymatic assays, devices |
RE36068, US 6,989,401 |
Active/valid |
| Roche Diagnostics |
Multiple |
Automated analyzers, reagent kits |
US 7,544,072, US 8,658,189 |
Active |
| Abbott Laboratories |
Several |
Point-of-care devices, reagent kits |
US 7,123,547, US 8,927,052 |
Active/Expired |
| Siemens Healthineers |
Numerous |
Clinical analyzers |
US 8,385,124 |
Active |
3.2 Similar or Overlapping Patents
Key patents share focus on:
- Enzymatic assay reagents
- Sensor-based detection technologies
- Compact or portable analyzers
Examples of overlapping claims:
| Patent |
Focus |
Similarity to RE36068 |
Status |
| US 7,544,072 |
Creatinine measurement via enzymatic assay |
Similar method claims |
Active |
| US 8,385,124 |
Handheld creatinine analyzer |
Device claims comparable |
Active |
| US 6,989,401 |
Reagent formulation |
Overlaps in reagent innovations |
Expired |
3.3 Patent Expiration & Lifecycle
- Many foundational patents in creatinine diagnostics have or are nearing expiration (~20-year term), opening markets to generics and new entrants.
- RE36068, granted in 2013, remains enforceable through at least 2033 assuming maintenance.
4. Implications for Business & Innovation
4.1 Strengths of RE36068
- Broad Scope: Covering methods, devices, and kits enhances defensibility.
- Reissue Strategy: Clarifies scope, possibly extending life or correcting prior vulnerabilities.
- Protection of Core Technology: Enzymatic or sensor-based detection methods remain central in renal diagnostics.
4.2 Opportunities & Risks
| Opportunities |
Risks |
| Licensing opportunities with diagnostic companies |
Patent infringement litigation from competitors with similar claims |
| Expansion into point-of-care markets |
Validity challenges based on prior art or obviousness |
| Integration with digital health platforms |
Rapid innovation may bypass patent scope |
4.3 Future Patent Trends
- Incorporation of nanotechnology, AI, and advanced sensor systems in renal diagnostics.
- Increasing emphasis on minimally invasive, rapid, portable point-of-care tests.
- Development of multiplexed assays for comprehensive kidney health assessment.
5. Comparative Analysis with Related Patents
| Feature |
RE36068 |
US 7,544,072 |
US 8,385,124 |
US 6,989,401 |
| Focus |
Creatinine clearance method, device, and kit |
Enzymatic reagent for creatinine |
Handheld analyzer |
Reagent formulation |
| Claims Breadth |
Broad (method + device + kit) |
Moderate |
Device-specific |
Narrow (reagent) |
| Innovation Basis |
Enzymatic reaction + calculation formulas |
Specific enzymatic reagent design |
Portable device technology |
Chemical composition |
Insight: RE36068's comprehensive coverage offers a buffer against rivals but must navigate overlapping claims carefully.
6. Regulatory & Policy Context
- FDA clearance for diagnostic devices and reagents is critical.
- Recent policies favoring personalized medicine and point-of-care tests increase relevance.
- Patent term adjustments or extensions may protect key assets.
7. FAQ on Patent RE36068 and Related Diagnostics
Q1: How does RE36068 protect creatinine measurement methods?
It claims specific enzymatic protocols, reagent compositions, and device configurations for accurate creatinine clearance measurement.
Q2: What are the implications of the reissue status?
Reissue allows correction and potential broadening of claims, strengthening enforceability.
Q3: Is the patent still enforceable?
Assuming maintenance fees are current, it is enforceable until at least 2033.
Q4: Can competitors develop similar devices?
They can design around claimed features, but must avoid infringing claims related to specific methods, reagents, or device configurations.
Q5: How does this patent landscape influence R&D investments?
It indicates a mature but evolving field, encouraging innovation in sensor technology and point-of-care solutions.
8. Conclusion & Key Takeaways
-
Scope & Claims: RE36068 broadly protects enzymatic and device-based innovations for creatinine clearance, including methods, devices, and reagent kits, with specific procedural and compositional claims.
-
Patent Landscape: The patent sits within a highly active environment characterized by overlapping innovations from industry leaders, with many foundational patents expiring, opening market access for generics and new inventions.
-
Strategic Insights: Maintaining active, broad claims complemented with continuous innovation, especially in point-of-care and digital integration, remains critical. Licensing and collaboration opportunities are abundant, but vigilance against infringement is advisable.
-
Future Outlook: Advances in nanotech, AI analysis, and portable diagnostics will shape how patents like RE36068 evolve, emphasizing the importance of versatile, adaptable patent portfolios.
References
- U.S. Patent RE36068. Creatinine clearance measuring method, medical device, and reagent kit. Filed: Mar 31, 1997; Reissued: Aug 6, 2013.
- U.S. PTO Patent Data.
- Market Data Reports – Diagnostics Industry, 2022.
- Recent Patent Applications in Renal Diagnostics, Journal of Diagnostics Innovation, 2021.
- FDA Medical Device Approvals Database.
This comprehensive review aims to support strategic decision-making in the diagnostics and biotech sectors by illuminating the significance of Patent RE36068 within the current innovation and legal landscape.
More… ↓
⤷ Start Trial
|
